SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19

被引:13
|
作者
Liang, Hong-Yu [1 ]
Wu, Yuyan [2 ,3 ]
Yau, Vicky [4 ]
Yin, Huan-Xin [1 ]
Lowe, Scott [5 ]
Bentley, Rachel [5 ]
Ahmed, Mubashir Ayaz [6 ]
Zhao, Wenjing [7 ]
Sun, Chenyu [7 ]
机构
[1] Anhui Med Univ, Sch Clin Med 2, Hefei 230032, Peoples R China
[2] First Peoples Hosp Hefei, 390 N Huaihe Rd, Hefei 230061, Peoples R China
[3] Philippine Womens Univ, Sch Nursing, 1743 Taft Ave, Manila 1004, Philippines
[4] Columbia Univ, Div Oral & Maxillofacial Surg, Irving Med Ctr, 622W 168th St, New York, NY 10032 USA
[5] Kansas City Univ, Coll Osteopath Med, 1750 Independence Ave, Kansas City, MO 64106 USA
[6] AMITA Hlth St Joseph Hosp Chicago, 2900 N Lake Shore Dr, Chicago, IL 60657 USA
[7] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Nantong Western Rd 98, Yangzhou 225000, Jiangsu, Peoples R China
关键词
COVID-19; SARS-CoV-2; variants; vaccines; molecular therapeutic target; RECEPTOR-BINDING DOMAIN; DELTA VARIANT; MUTATIONS; ESCAPE; SPIKE; ACE2; NEUTRALIZATION; INFECTION; ANAKINRA; SCOTLAND;
D O I
10.3390/vaccines10091538
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants.
引用
收藏
页数:27
相关论文
共 50 条
  • [1] SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
    Gong, Wenping
    Parkkila, Seppo
    Wu, Xueqiong
    Aspatwar, Ashok
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2023, 42 (06) : 393 - 414
  • [2] COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
    Raman, Renuka
    Patel, Krishna J.
    Ranjan, Kishu
    BIOMOLECULES, 2021, 11 (07)
  • [3] Role of COVID-19 Vaccines in SARS-CoV-2 Variants
    Zhou, Zhou
    Zhu, Yimiao
    Chu, Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
    McLean, Gary
    Kamil, Jeremy
    Lee, Benhur
    Moore, Penny
    Schulz, Thomas F.
    Muik, Alexander
    Sahin, Ugur
    Tureci, Ozlem
    Pather, Shanti
    MBIO, 2022, 13 (02):
  • [5] SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
    Dao, Thi Loi
    Hoang, Van Thuan
    Colson, Philippe
    Lagier, Jean Christophe
    Million, Matthieu
    Raoult, Didier
    Levasseur, Anthony
    Gautret, Philippe
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
  • [6] The variants of SARS-CoV-2 and the challenges of vaccines
    Han, Xiucui
    Ye, Qing
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (04) : 1366 - 1372
  • [7] An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
    Hillary, Varghese Edwin
    Ceasar, Stanislaus Antony
    HELIYON, 2023, 9 (03)
  • [8] Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19
    Ramos, A. M.
    Vela-Perez, M.
    Ferrandez, M. R.
    Kubik, A. B.
    Ivorra, B.
    COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION, 2021, 102
  • [9] Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
    Fiolet, Thibault
    Kherabi, Yousra
    MacDonald, Conor-James
    Ghosn, Jade
    Peiffer-Smadja, Nathan
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (02) : 202 - 221
  • [10] SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
    Uddin, Mohammed
    Mustafa, Farah
    Rizvi, Tahir A.
    Loney, Tom
    Al Suwaidi, Hanan
    Al-Marzouqi, Ahmed H. Hassan
    Eldin, Afaf Kamal
    Alsabeeha, Nabeel
    Adrian, Thomas E.
    Stefanini, Cesare
    Nowotny, Norbert
    Alsheikh-Ali, Alawi
    Senok, Abiola C.
    VIRUSES-BASEL, 2020, 12 (05):